What is the difference between the primary endpoint in the adult/adolescent trials and the trial with children (6-11 years of age)?

In the adult trials with DUPIXENT monotherapy (SOLO 1 and SOLO 2) and with concomitant topical corticosteroids (CHRONOS), as well as the adolescent trial (AD-1526), the primary endpoint was the change in baseline to Week 16 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and a ≥2-point improvement in patients with a baseline IGA of 3 (moderate) or 4 (severe).¹

In the trial in children (AD-1652), the primary endpoint was the change in baseline at Week 16 in the proportion of subjects with an IGA 0 or 1 in patients with a baseline IGA of 4.¹